Metabolic Disorders, Cancer, Drug Development, Drug Design

The incidence of metabolic disorders is increasing all over the world and especially in technologically advanced countries due to the many cofactors involved. Among them are environmental factors (like contaminants, pollution, as well as climatic changes), antigenic pressure in particular from microbial infections, life style disorders like alcohol, smoking or diet, as well as alteration of intestinal microbiota. All these factors seem to represent the major etiopathogenic determinants for the development of metabolic disorders, which are in many cases systemic and therefore connected to such diseases resulting in the contribution of pathology. Furthermore, a lot of studies show that most of these pathologies contribute towards further cardiovascular, hematological, gastrointestinal as well as cancer development.

Therefore, in the proposed special issue for Current Pharmaceutical Design, entitled ‘Drug Design for Metabolic Disorders and Cancer’s we plan to collect updates in the field of development of novel pharmaceuticals aimed to treat the pathological that affect metabolisms within various endocrine, cardiovascular, hematological, immune and gastrointestinal systems.

The field of the development of pharmaceuticals targets specific cancer metabolisms will also be covered.

We are confident that this issue will shed more light on the mechanisms connecting and amplifying metabolic processes and cancer, as well as from the standpoint of design and development of novel drugs effective in the treatment of these diseases.

Schedule:

Manuscript submission deadline: July 10, 2015
Peer review due: August 10, 2015
Revision due: August 31, 2015
Notification of acceptance by the Guest Editor: September 10, 2015
Final Manuscript Due: September 15, 2015